Names and pronunciation
(a′fa-me-lan′oh-tide) Scenesse
PDF page 41
Loading InternPractice…
Drug reference
(a′fa-me-lan′oh-tide) Scenesse
PDF page 41
Func. class.: Dermatologic agent
PDF page 41
Chem. class.: Melanocortin receptor agonist
PDF page 41
ACTION: Increases production of eumelanin in the skin without exposure to sunlight or arti- ficial UV light
PDF page 41
USES: To increase light exposure in those with phototoxic reactions from erythropoietic protoporphyria
PDF page 41
CONTRAINDICATIONS None Precautions: Not approved in children
PDF page 41
SIDE EFFECTS CNS: Dizziness, fatigue, drowsiness GI: Nausea INTEG: Site reaction, melanocytic nevus, A hyperpigmentation, skin irritation/ discoloration ENDO: Porphyria RESP: Oropharyngeal pain, cough, respi ratory tract infection
PDF page 41
INTERACTIONS None known
PDF page 41
DOSAGE AND ROUTES • Adult: SUBCUT 16 mg implanted above the anterior suprailiac crest q2mo
PDF page 41
Available forms: Implant, SUBCUT 16 mg
PDF page 41
Administer: • This product should be implanted by a health care professional proficient in the SUBCUT implantation procedure • Patients should maintain sun and light protection measures during treatment to prevent phototoxic reactions • Monitor patient for 30 min after im- plant • Leave dressing in place for 24 hr • Store in refrigerator, protect from light
PDF page 41
Assess: • Skin pigmentation: Increased skin pigmentation and darkening of preexisting nevi and ephelides may occur; obtain a full-body skin examination (twice yearly) • Phototoxic reactions: Maintain sun and light protection measures during treatment to prevent phototoxic reactions • Pregnancy/breastfeeding: Not known if safe in pregnancy or breastfeeding
PDF page 41
Evaluate: • Therapeutic response: Prevention of phototoxic reactions
PDF page 41
CLINICAL CONSIDERATIONS
PDF page 41
Patient and caregiver information: • To contact their health care provider if implant is expelled • To remove dressing 24 hr after implant • To monitor site and report reactions to their health care provider • To maintain sun and light protection measures during treatment • That darkening of preexisting nevi or other skin abnormalities may occur • To schedule twice-yearly full-body skin exams HIGH ALERT
PDF page 41
PHARMACOKINETICS Onset unknown, peak 36 hr, duration 96 hr, half-life 15 hr
PDF page 41
• Adult: SUBCUT 16 mg implanted above the anterior suprailiac crest q2mo
PDF page 41